Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

Effects Of GW679769 On Sleep Onset And Maintenance,And Next Day Functioning In The Elderly And Non-elderly With Primary Insomnia

ClinicalTrials.gov ID: NCT00280436

Public ClinicalTrials.gov record NCT00280436. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind, Placebo-controlled, Cross-over Study to Evaluate the Effects of GW679769 on Polysomnographic Sleep Recordings, Subjective Sleep Assessment, and Daytime Cognitive Function in Elderly and Non-elderly Subjects With Primary Insomnia

Study identification

NCT ID
NCT00280436
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
122 participants

Conditions and interventions

Interventions

  • GW679769 Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 31, 2005
Primary completion
Feb 28, 2007
Completion
Feb 28, 2007
Last update posted
Apr 15, 2015

2006 – 2007

United States locations

U.S. sites
26
U.S. states
15
U.S. cities
24
Facility City State ZIP Site status
GSK Investigational Site Phoenix Arizona 85050
GSK Investigational Site Tucson Arizona 85710
GSK Investigational Site Anaheim California 92805
GSK Investigational Site Glendale California 91204
GSK Investigational Site Glendale California 91206
GSK Investigational Site Redlands California 92373
GSK Investigational Site San Diego California 92103
GSK Investigational Site San Diego California 92123
GSK Investigational Site Brandon Florida 33511
GSK Investigational Site Kissimmee Florida 34741
GSK Investigational Site Naples Florida 34110
GSK Investigational Site Spring Hill Florida 34609
GSK Investigational Site Austell Georgia 30106
GSK Investigational Site Chicago Illinois 60634
GSK Investigational Site Northfield Illinois 60093
GSK Investigational Site Overland Park Kansas 66211
GSK Investigational Site Chevy Chase Maryland 20815
GSK Investigational Site Frederick Maryland 21702
GSK Investigational Site Lincoln Nebraska 68510
GSK Investigational Site Raleigh North Carolina 27612
GSK Investigational Site Oklahoma City Oklahoma 73112
GSK Investigational Site Lafayette Hill Pennsylvania 19444
GSK Investigational Site Warwick Rhode Island 02886
GSK Investigational Site Anderson South Carolina 29621
GSK Investigational Site Austin Texas 78756
GSK Investigational Site Fairfax Virginia 22030

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00280436, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 15, 2015 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00280436 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →